Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Telix to Supply Bayer with Illuccix® for Global Phase III Prostate Cancer Study
Telix Pharmaceuticals today announces that it has entered into an agreement with Bayer AG (Bayer) […]
Bayer Expands Global Clinical Program for NUBEQA® (darolutamide) in Prostate Cancer
Bayer further expands the global clinical development program for NUBEQA (darolutamide) in prostate cancer. The […]
Phase 3 Study Shows XTANDI® (enzalutamide) plus Leuprolide Significantly Improves Metastasis-Free Survival in Men with Non-Metastatic Prostate Cancer
Pfizer and Astellas Pharma have announced positive topline results from the Phase 3 EMBARK trial […]
ARX517 Shows Encouraging Single-Agent Safety and Efficacy Data in Patients with Advanced Prostate Cancer
Ambrx Biopharma today announced encouraging initial data from its ongoing Phase 1 trial investigating ARX517, […]
Fusion Pharmaceuticals to Acquire Phase 2 Program for 225Ac-PSMA I&T, a Radiopharmaceutical Targeting Metastatic Castrate Resistant Prostate Cancer
Fusion Pharmaceuticals, a clinical-stage oncology company focused on developing next-generation targeted alpha therapies as precision […]
U.S.-based COBRA Diagnostic Prostate Cancer Trial Reaches Recruitment Target
Clarity Pharmaceuticals, a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more